@article{b862bd463600470a9317a8035f92d619,
title = "Δcps1 vaccine protects dogs against experimentally induced coccidioidomycosis",
abstract = "Coccidioidomycosis is a significant health problem of dogs and humans in endemic regions, especially California and Arizona in the U.S. Both species would greatly benefit from a vaccine to prevent this disease. A live avirulent vaccine candidate, Δcps1, was tested for tolerability and efficacy to prevent pulmonary coccidioidomycosis in a canine challenge model. Vaccine injection-site reactions were transient and there were no systemic effects observed. Six of seven vaccine sites tested and all draining lymph nodes were sterile post-vaccination. Following infection with Coccidioides posadasii, strain Silveira, arthroconidia into the lungs, dogs given primary and booster vaccinations had significantly reduced lung fungal burdens (P = 0.0003) and composite disease scores (P = 0.0002) compared to unvaccinated dogs. Dogs vaccinated once had fungal burdens intermediate between those given two doses or none, but disease scores were not significantly different from unvaccinated (P = 0.675). Δcps1 was well-tolerated in the dogs and it afforded a high level of protection when given as prime and boost. These results drive the Δcps1 vaccine toward a licensed veterinary vaccine and support continued development of this vaccine to prevent coccidioidomycosis in humans.",
keywords = "Avirulent, Coccidioidomycosis, Dogs, Fungal, Vaccine",
author = "Shubitz, {Lisa F.} and Robb, {Edward J.} and Powell, {Daniel A.} and Bowen, {Richard A.} and Angela Bosco-Lauth and Airn Hartwig and Porter, {Stephanie M.} and Hien Trinh and Hilary Moale and Helle Bielefeldt-Ohmann and James Hoskinson and Orbach, {Marc J.} and Frelinger, {Jeffrey A.} and Galgiani, {John N.}",
note = "Funding Information: We thank DJ Rezac and staff at Veterinary and Biomedical Research Center, Inc, for vaccinating and assessing reactions in the dogs; Lourdes Lewis and Margaret McDermott for preparation of fungal cultures; Joe Wheat, Nicole Bridges, and Michelle Durkin at MiraVista Diagnostics for collaboration on serology. We thank Tom Monath and Lynda Tussey for reading the manuscript and suggesting insightful improvements. This work was funded by the National Institutes of Allergy and Infectious Disease [grant number RO1-AI-132140] and Anivive Lifesciences, LLC, Long Beach, CA. Funding Information: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [John N Galgiani reports financial support was provided by National Institutes of Health. Edward Robb reports financial support and equipment, drugs, or supplies were provided by Anivive Life Sciences, LLC. Edward Robb reports a relationship with Anivive Lifesciences, LLC that includes: employment.. Lisa Shubitz has patent #Fungal lmmunogens and Related Materials and Methods WO2014164843-A1 issued to Arizona Board of Regents. Marc Orbach has patent #Fungal lmmunogens and Related Materials and Methods WO2014164843-A1 issued to Arizona Board of Regents.]. Funding Information: This work was funded by the National Institutes of Allergy and Infectious Disease [grant number RO1-AI-132140] and Anivive Lifesciences, LLC, Long Beach, CA. Publisher Copyright: {\textcopyright} 2021",
year = "2021",
month = nov,
day = "16",
doi = "10.1016/j.vaccine.2021.10.029",
language = "English (US)",
volume = "39",
pages = "6894--6901",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "47",
}